Agile Therapeutics
AGRX
AGRX was delisted on the 25th of March, 2024.
18 hedge funds and large institutions have $70.2M invested in Agile Therapeutics in 2014 Q2 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
Investor AB
Stockholm,
Sweden
|
+$25.4M |
| 2 |
AC
Aisling Capital
New York
|
+$15.7M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.68M |
| 4 |
RA
Royce & Associates
New York
|
+$2.43M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.29M |
Top Sellers
AGRX Hedge Fund Activity: Q2 2014 in Review
18 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Agile Therapeutics (AGRX) for Q2 2014, worth a combined $70.2M.
Buyers outnumbered sellers: 18 funds opened new AGRX positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Investor AB, opening a new position worth an estimated $25.4M.
- 18 institutional investors held Agile Therapeutics (AGRX) as of Q2 2014, up from 0 in Q1 2014.
- Funds reported $70.2M of Agile Therapeutics stock for Q2 2014.
- 18 funds opened new Agile Therapeutics positions in Q2 2014 and 0 closed out, a net change of +18 holders.
- The largest Agile Therapeutics buyer in Q2 2014 was Investor AB, an estimated $25.4M added.
Based on aggregated 13F filings for Q2 2014.